Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Pyxis is focused on developing next-generation therapies to target difficult-to-treat cancers, with a broad portfolio of novel antibody drug conjugate (ADC) candidates and monoclonal antibody (mAb) preclinical discovery programs. It is developing its ADC candidates and mAb preclinical discovery programs for difficult-to-treat solid and hematologic tumors. Pyxis anticipates submitting INDs for two of its ADC candidates by mid-2022, and another candidate by 2023.
The Cambridge, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol PYXO. Pyxis Oncology filed confidentially on June 21, 2021. BofA Securities, Jefferies, Credit Suisse, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.